Varicella prevention in the United States: A review of successes and challenges

Pediatrics

Volumn 122, Issue 3, 2008, Pages

  Marin, Mona ^a,c   Meissner, H Cody ^b   Seward, Jane F ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Chickenpox; Varicella; Varicella epidemiology; Varicella vaccination program; Varicella vaccine

Indexed keywords

CHICKENPOX VACCINE; VIRUS VACCINE;

ANTIBODY TITER; BIBLIOGRAPHIC DATABASE; CEREBELLAR ATAXIA; CHICKENPOX; DISEASE SEVERITY; DRUG EFFICACY; FEVER; HEALTH CARE COST; HEMIPARESIS; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INCIDENCE; INJECTION SITE REACTION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT FAILURE; UNITED STATES; VACCINATION; CHILD; IMMUNOLOGY; INFECTION CONTROL; PREVALENCE; VARICELLA ZOSTER VIRUS;

CHICKENPOX; CHILD; HERPESVIRUS 3, HUMAN; HUMANS; INFECTION CONTROL; PREVALENCE; UNITED STATES; VACCINATION; VIRAL VACCINES;

EID: 51649087202     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-0567     Document Type: Review

References (92)

1. Centers for Disease Control and Prevention. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1996; 45(RR-11):1-36
2. American Academy of Pediatrics, Committee on Infectious Diseases. Recommendations for the use of live attenuated varicella vaccine [published correction appears in Pediatrics. 1995;96(1 pt 1):preceding 151, following 171]. Pediatrics. 1995;95(5):791-796
3. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287(5):606-611
4. Guris D, Jumaan AO, Mascola L, et al. Changing varicella epidemiology in active surveillance sites: United States, 1995-2005. J Infect Dis. 2008;197(suppl 2):S71-S75
5. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. JAMA. 2005; 294(7):797-802
6. Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics. 2004;114(3):786-792
7. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med. 2005;352(5):450-458
8. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-4):1-40
9. American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule. Pediatrics. 2007;120(1):221-231
10. Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am. 1996;10(3):571-581
11. Gershon AA, Takahashi M, Seward JF. Varicella vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: Sanders; 2007:915-958
12. Yawn BP, Yawn RA, Lydick E. Community impact of childhood varicella infections. J Pediatr. 1997;130(5):759-765
13. Finger R, Hughes JP, Meade BJ, Pelletier AR, Palmer CT. Age-specific incidence of chickenpox. Public Health Rep. 1994; 109(6):750-755
14. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-S118
15. Galil K, Brown C, Lin F, Seward J. Hospitalizations for varicella in the United States, 1988 to 1999. Pediatr Infect Dis J. 2002; 21(10):931-935
16. Ratner AJ. Varicella-related hospitalizations in the vaccine era. Pediatr Infect Dis J. 2002;21(10):927-931
17. Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis. 2000;182(2):383-390
18. National, state, and local area vaccination coverage among children aged 19-35 months: United States, 2006. MMWR Morb Mortal Wkly Rep. 2007;56(34):880-885
19. Luman ET, Ching PL, Jumaan AO, Seward JF. Uptake of varicella vaccination among young children in the United States: a success story in eliminating racial and ethnic disparities. Pediatrics. 2006;117(4):999-1008
20. McNabb SJ, Jajosky RA, Hall-Baker PA, et al. Summary of notifiable diseases: United States, 2005. MMWR Morb Mortal Wkly Rep. 2007;54(53):1-92
21. Galil K, Pletcher MJ, Wallace BJ, et al. Tracking varicella deaths: accuracy and completeness of death certificates and hospital discharge records, New York State, 1989-1995. Am J Public Health. 2002;92(8):1248-1250
22. Outbreak of varicella among vaccinated children: Michigan, 2003. MMWR Morb Mortal Wkly Rep. 2004;53(18):389-392
23. Varicella outbreak among vaccinated children: Nebraska, 2004. MMWR Morb Mortal Wkly Rep. 2006;55(27):749-752
24. Buchholz U, Moolenaar R, Peterson C, Mascola L. Varicella outbreaks after vaccine licensure: should they make you chicken? Pediatrics. 1999;104(3 pt 1):561-563
25. Clements DA, Moreira SP, Coplan PM, Bland CL, Walter EB. Postlicensure study of varicella vaccine effectiveness in a day- care setting. Pediatr Infect Dis J. 1999;18(12):1047-1050
26. Dworkin MS, Jennings CE, Roth-Thomas J, Lang JE, Stukenberg C, Lumpkin JR. An outbreak of varicella among children attending preschool and elementary school in Illinois. Clin Infect Dis. 2002;35(1):102-104
27. Galil K, Fair E, Mountcastle N, Britz P, Seward J. Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis. 2002;186(1):102-105
28. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med. 2002;347(24):1909-1915
29. Haddad MB, Hill MB, Pavia AT, et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics. 2005;115(6):1488-1493
30. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA. 1997;278(18):1495-1499
31. Lee BR, Feaver SL, Miller CA, Hedberg CW, Ehresmann KR. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J Infect Dis. 2004;190(3):477-483
32. Lopez AS, Guris D, Zimmerman L, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics. 2006;117(6). Available at: www.pediatrics.org/cgi/content/full/117/6/e1070
33. Marin M, Nguyen HQ, Keen J, et al. Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003. Pediatrics. 2005;115(4):900-905
34. Parker A, Reynolds M, Leung J, et al. Challenges to implementing second dose varicella vaccination during an outbreak in the absence of a routine two-dose vaccination requirement: Maine, 2006. J Infect Dis. 2008;197:S101-S108
35. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA. 2004;292(6):704-708
36. Tugwell BD, Lee LE, Gillette H, Lorber EM, Hedberg K, Cieslak PR. Chickenpox outbreak in a highly vaccinated school population. Pediatrics. 2004;113(3 pt 1):455-459
37. Vázquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA. 2004;291(7):851-855
38. Vázquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344(13):955-960
39. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med. 1984;310(22):1409-1415
40. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics. 1986;78(4 pt 2):748 -756
41. Krause PR, Klinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr. 1995; 127(4):518-525
42. White CJ, Kuter BJ, Hildebrand CS, et al. Varicella vaccine (Varivax) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics. 1991;87(5):604-610
43. Seward JF, Marin M, Vasquez M. Varicella vaccine effectiveness in the United States vaccination program: a review. J Infect Dis. 2008;197(suppl 2):S82-S89
44. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23(2):132-137
45. Verstraeten T, Jumaan AO, Mullooly JP, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumpsrubella vaccination. Pediatrics. 2003;112(2). Available at: www.pediatrics.org/cgi/content/full/112/2/e98
46. Black S, Ray P, Shinefield H, Saddier P, Nikas A. Lack of association between age at varicella vaccination and risk of breakthrough varicella, within Northern California Kaiser Permanente Medical Care Program. J Infect Dis. 2008;197:S139 -S142
47. Silber JL, Chan IS, Wang WW, Matthews H, Kuter BJ. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age. Pediatr Infect Dis J. 2007;26(7):572-576
48. Bayer O, Heininger U, Heiligensetzer C, von Kries R. Meta-analysis of vaccine effectiveness in varicella outbreaks. Vaccine. 2007;25(37-38):6655-6660
49. Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine- induced immunity to varicella over time. N Engl J Med. 2007; 356(11):1121-1129
50. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine. 2000;19(7-8):916 -923
51. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA. 2000;284(10):1271-1279
52. Chaves SS, Haber P, Walton K, et al. Post-licensure safety of varicella vaccine in the United States: experience from reports to the Vaccine Adverse Event Reporting System, 1995-2005. J Infect Dis. 2008;197(suppl 2):S170-S177
53. Grossberg R, Harpaz R, Rubtcova E, Loparev V, Seward JF, Schmid DS. Secondary transmission of varicella vaccine virus in a chronic care facility for children. J Pediatr. 2006;148(6):842-844
54. Salzman MB, Sharrar RG, Steinberg S, LaRussa P. Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother. J Pediatr. 1997;131(1 pt 1):151-154
55. Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr. 1990;116(2):184-189
56. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep. 2008;57(10):258-260
57. Vessey SJ, Chan CY, Kuter BJ, et al. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. J Pediatr. 2001;139(2):297-304
58. Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics. 1993;91(1):17-22
59. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J. 1992;11(1):19-23
60. Chaves SS, Zhang JX, Civen R, et al. Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005. J Infect Dis. 2008;197(suppl 2):S127-S131
61. Chan IS, Li S, Matthews H, et al. Use of statistical models for evaluating antibody response as a correlate of protection against varicella. Stat Med. 2002;21(22):3411-3430
62. Li S, Chan IS, Matthews H, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J. 2002;21(4):337-342
63. Michalik DE, Steinberg SP, LaRussa PS, et al. Primary vaccine failure after one dose of varicella vaccine in healthy children. J Infect Dis. 2008;197(7):944-949
64. Varivax (varicella virus vaccine live) [package insert]; White-house Station, NJ; Merck amp; Co Inc: 2001
65. Nader S, Bergen R, Sharp M, Arvin AM. Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis. 1995;171(1):13-17
66. Reisinger KS, Brown ML, Xu J, et al. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) givento 4- to 6-year-old healthy children vaccinated previously with M-M- RII and Varivax [published correction appears in Pediatrics. 2006117(6):2338]. Pediatrics. 2006;117(2):265-272
67. Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24(8):665-669
68. Watson B, Boardman C, Laufer D, et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis. 1995;20(2): 316-319
69. Watson B, Rothstein E, Bernstein H, et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis. 1995; 172(1):217-219
70. Zhou F, Ortega-Sanchez I, Guris D, Lieu T, Seward JF. An economic analysis of the universal varicella vaccination program in the United States. J Infect Dis. 2008;197(suppl 2):S156-S164
71. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine. 2002;20(19-20):2500-2507
72. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9-20
73. Solomon BA, Kaporis AG, Glass AT, Simon SI, Baldwin HE. Lasting immunity to varicella in doctors study (L.I.V.I.D. study). J Am Acad Dermatol. 1998;38(5 pt 1):763-765
74. Terada K, Hiraga Y, Kawano S, Kataoka N. Incidence of herpes zoster in pediatricians and history of reexposure to varicellazoster virus in patients with herpes zoster [in Japanese]. Kansenshogaku Zasshi. 1995;69(8):908-912
75. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet. 2002;360(9334):678-682
76. Garnett GP, Ferguson NM. Predicting the effect of varicella vaccine on subsequent cases of zoster and varicella. Rev Med Virol. 1996;6(3):151-161
77. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med. 1991;325(22): 1545-1550
78. Black S, Shinefield H, Ray P, et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J. 1999;18(12):1041-1046
79. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella- vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis. 2005;191(12):2002- 2007
80. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect. 2005;133(2):245-253
81. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748-753
82. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995;155(15):1605-1609
83. Yih WK, Brooks DR, Lett SM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998 -2003. BMC Public Health. 2005;5(1):68
84. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349
85. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127(2):305-314
86. Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982;61(5):310-316
87. Russell ML, Schopflocher DP, Svenson L, Virani SN. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect. 2007;135(6):908-913
88. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;57 (RR-5):1-30
89. Takayama N, Takayama M, Takita J. Herpes zoster in healthy children immunized with varicella vaccine. Pediatr Infect Dis J. 2000;19(2):169-170
90. Lawrence R, Gershon AA, Holzman R, Steinberg SP. The risk of zoster after varicella vaccination in children with leukemia. N Engl J Med. 1988;318(9):543-548
91. White CJ. Clinical trials of varicella vaccine in healthy children. Infect Dis Clin North Am. 1996;10(3):595-608
92. Hirsch MS, Hooper DC, eds. J Infect Dis. 2008:197(suppl 2):S1-S245